Document Type
Article
Publication Date
11-1-2019
Abstract
Quantum dots (QDs) conjugated with 1,25 dihydroxyvitamin D3 (calcitriol) and Mucin-1 (MUC-1) antibodies (SM3) have been found to target inflammatory breast cancer (IBC) tumors and reduce proliferation, migration, and differentiation of these tumors in mice. A physiologically-based pharmacokinetic model has been constructed and optimized to match experimental data for multiple QDs: control QDs, QDs conjugated with calcitriol, and QDs conjugated with both calcitriol and SM3 MUC1 antibodies. The model predicts continuous QD concentration for key tissues in mice distinguished by IBC stage (healthy, early-stage, and late-stage). Experimental and clinical efforts in QD treatment of IBC can be augmented by in silico simulations that predict the short-term and long-term behavior of QD treatment regimens.
Recommended Citation
Forder, James; Smith, Mallory; Wagner, Margot; Schaefer, Rachel J.; Gorky, Jonathan; van Golen, Kenneth L.; Nohe, Anja; and Dhurjati, Prasad, "A Physiologically-Based Pharmacokinetic Model for Targeting Calcitriol-Conjugated Quantum Dots to Inflammatory Breast Cancer Cells." (2019). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper 289.
https://jdc.jefferson.edu/pacbfp/289
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
31305024
Language
English
Comments
This article is the author’s final published version in Clinical and Translational Science, Volume 12, Issue 6, November 2019, Pages 617-624.
The published version is available at https://doi.org/10.1111/cts.12664. Copyright © Forder et al.